6lqa: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 3: Line 3:
<StructureSection load='6lqa' size='340' side='right'caption='[[6lqa]], [[Resolution|resolution]] 3.30&Aring;' scene=''>
<StructureSection load='6lqa' size='340' side='right'caption='[[6lqa]], [[Resolution|resolution]] 3.30&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[6lqa]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LQA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LQA FirstGlance]. <br>
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LQA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LQA FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=QDN:QUINIDINE'>QDN</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.3&#8491;</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">SCN5A ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=QDN:QUINIDINE'>QDN</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lqa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lqa OCA], [https://pdbe.org/6lqa PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lqa RCSB], [https://www.ebi.ac.uk/pdbsum/6lqa PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lqa ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lqa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lqa OCA], [https://pdbe.org/6lqa PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lqa RCSB], [https://www.ebi.ac.uk/pdbsum/6lqa PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lqa ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
[[https://www.uniprot.org/uniprot/SCN5A_HUMAN SCN5A_HUMAN]] Defects in SCN5A are a cause of progressive familial heart block type 1A (PFHB1A) [MIM:[https://omim.org/entry/113900 113900]]; also known as Lenegre-Lev disease or progressive cardiac conduction defect (PCCD). PFHB1A is an autosomal dominant cardiac bundle branch disorder that may progress to complete heart block. PFHB1A is characterized by progressive alteration of cardiac conduction through the His-Purkinje system with right or left bundle branch block and widening of QRS complexes, leading to complete atrioventricular block and causing syncope and sudden death.<ref>PMID:10471492</ref> <ref>PMID:11234013</ref> <ref>PMID:11804990</ref> <ref>PMID:12574143</ref> <ref>PMID:12569159</ref> <ref>PMID:19251209</ref>  Defects in SCN5A are the cause of long QT syndrome type 3 (LQT3) [MIM:[https://omim.org/entry/603830 603830]]. Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress. LQT3 inheritance is an autosomal dominant.<ref>PMID:10471492</ref> <ref>PMID:12454206</ref> <ref>PMID:7889574</ref> <ref>PMID:8541846</ref> <ref>PMID:7651517</ref> <ref>PMID:9686753</ref> <ref>PMID:9506831</ref> <ref>PMID:10627139</ref> [:]<ref>PMID:10508990</ref> <ref>PMID:10377081</ref> <ref>PMID:10590249</ref> <ref>PMID:10973849</ref> <ref>PMID:10911008</ref> <ref>PMID:11304498</ref> <ref>PMID:11410597</ref> <ref>PMID:11710892</ref> <ref>PMID:11889015</ref> <ref>PMID:11997281</ref> <ref>PMID:12209021</ref> <ref>PMID:12673799</ref> <ref>PMID:15840476</ref> <ref>PMID:16922724</ref> <ref>PMID:18708744</ref> <ref>PMID:18060054</ref> <ref>PMID:18929331</ref> <ref>PMID:18848812</ref> <ref>PMID:18451998</ref> <ref>PMID:21109022</ref>  Defects in SCN5A are the cause of Brugada syndrome type 1 (BRGDA1) [MIM:[https://omim.org/entry/601144 601144]]. An autosomal dominant tachyarrhythmia characterized by right bundle branch block and ST segment elevation on an electrocardiogram (ECG). It can cause the ventricles to beat so fast that the blood is prevented from circulating efficiently in the body. When this situation occurs (called ventricular fibrillation), the individual will faint and may die in a few minutes if the heart is not reset.<ref>PMID:10471492</ref> <ref>PMID:19251209</ref> <ref>PMID:11410597</ref> <ref>PMID:9521325</ref> <ref>PMID:10690282</ref> <ref>PMID:10532948</ref> <ref>PMID:10618304</ref> <ref>PMID:12106943</ref> <ref>PMID:11901046</ref> <ref>PMID:11823453</ref> <ref>PMID:12051963</ref> <ref>PMID:15023552</ref> <ref>PMID:15338453</ref> <ref>PMID:15579534</ref> <ref>PMID:16266370</ref> <ref>PMID:15851320</ref> <ref>PMID:16325048</ref> <ref>PMID:16616735</ref> <ref>PMID:17075016</ref> <ref>PMID:17081365</ref> <ref>PMID:17198989</ref> <ref>PMID:18341814</ref> <ref>PMID:18616619</ref> <ref>PMID:18456723</ref> <ref>PMID:18252757</ref> <ref>PMID:19272188</ref>  Defects in SCN5A are the cause of sick sinus syndrome type 1 (SSS1) [MIM:[https://omim.org/entry/608567 608567]]. The term 'sick sinus syndrome' encompasses a variety of conditions caused by sinus node dysfunction. The most common clinical manifestations are syncope, presyncope, dizziness, and fatigue. Electrocardiogram typically shows sinus bradycardia, sinus arrest, and/or sinoatrial block. Episodes of atrial tachycardias coexisting with sinus bradycardia ('tachycardia-bradycardia syndrome') are also common in this disorder. SSS occurs most often in the elderly associated with underlying heart disease or previous cardiac surgery, but can also occur in the fetus, infant, or child without heart disease or other contributing factors, in which case it is considered to be a congenital disorder.<ref>PMID:10471492</ref> <ref>PMID:11748104</ref> <ref>PMID:14523039</ref> <ref>PMID:22795782</ref>  Defects in SCN5A are the cause of familial paroxysmal ventricular fibrillation type 1 (VF1) [MIM:[https://omim.org/entry/603829 603829]]. A cardiac arrhythmia marked by fibrillary contractions of the ventricular muscle due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricle and by absence of atrial activity.<ref>PMID:10471492</ref> <ref>PMID:10940383</ref>  Defects in SCN5A may be a cause of sudden infant death syndrome (SIDS) [MIM:[https://omim.org/entry/272120 272120]]. SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive. Long QT syndromes-associated mutations can be responsible for some of SIDS cases.<ref>PMID:10471492</ref> <ref>PMID:18596570</ref> <ref>PMID:19302788</ref>  Defects in SCN5A may be a cause of familial atrial standstill (FAS) [MIM:[https://omim.org/entry/108770 108770]]. Atrial standstill is an extremely rare arrhythmia, characterized by the absence of electrical and mechanical activity in the atria. Electrocardiographically, it is characterized by bradycardia, the absence of P waves, and a junctional narrow complex escape rhythm.<ref>PMID:10471492</ref> <ref>PMID:12522116</ref>  Defects in SCN5A are the cause of cardiomyopathy dilated type 1E (CMD1E) [MIM:[https://omim.org/entry/601154 601154]]; also known as dilated cardiomyopathy with conduction disorder and arrhythmia or dilated cardiomyopathy with conduction defect 2. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.<ref>PMID:10471492</ref> <ref>PMID:15466643</ref>  Defects in SCN5A are the cause of familial atrial fibrillation type 10 (ATFB10) [MIM:[https://omim.org/entry/614022 614022]]. ATFB10 is a familial form of atrial fibrillation, a common sustained cardiac rhythm disturbance. Atrial fibrillation is characterized by disorganized atrial electrical activity and ineffective atrial contraction promoting blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure.<ref>PMID:10471492</ref> <ref>PMID:18378609</ref> <ref>PMID:18088563</ref> 
== Function ==
[[https://www.uniprot.org/uniprot/SCN5A_HUMAN SCN5A_HUMAN]] This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is responsible for the initial upstroke of the action potential. Channel inactivation is regulated by intracellular calcium levels.<ref>PMID:19074138</ref> 
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 21: Line 17:
</div>
</div>
<div class="pdbe-citations 6lqa" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6lqa" style="background-color:#fffaf0;"></div>
==See Also==
*[[Ion channels 3D structures|Ion channels 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Huang, G]]
[[Category: Huang G]]
[[Category: Li, Z]]
[[Category: Li Z]]
[[Category: Pan, X]]
[[Category: Pan X]]
[[Category: Yan, N]]
[[Category: Yan N]]
[[Category: Membrane protein]]
[[Category: Transport protein]]
[[Category: Voltage-gated sodium channel]]

Latest revision as of 15:50, 6 November 2024

voltage-gated sodium channel Nav1.5 with quinidinevoltage-gated sodium channel Nav1.5 with quinidine

Structural highlights

Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:Electron Microscopy, Resolution 3.3Å
Ligands:,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Publication Abstract from PubMed

Na v 1.5, the primary voltage-gated Na + (Na v ) channel in heart, is a major target for class I antiarrhythmic agents. Here we present the cryo-EM structure of full-length human Na v 1.5 bound to quinidine, a class Ia antiarrhythmic drug, at 3.3 A resolution. Quinidine is positioned right beneath the selectivity filter in the pore domain and coordinated by residues from repeats I, III, and IV. Pore blockade by quinidine is achieved through both direct obstruction of the ion permeation path and induced rotation of an invariant Tyr residue that tightens the intracellular gate. Structural comparison with a truncated rat Na v 1.5 in the presence of flecainide, a class Ic agent, reveals distinct binding poses for the two antiarrhythmics within the pore domain. Our work reported here, along with previous studies, reveals the molecular basis for the mechanism of action of class I antiarrhythmic drugs.

Structural Basis for Pore Blockade of the Human Cardiac Sodium Channel Nav1.5 by the Antiarrhythmic Drug Quinidine.,Li Z, Jin X, Wu T, Huang G, Wu K, Lei J, Pan X, Yan N Angew Chem Int Ed Engl. 2021 Mar 8. doi: 10.1002/anie.202102196. PMID:33684260[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Li Z, Jin X, Wu T, Huang G, Wu K, Lei J, Pan X, Yan N. Structural Basis for Pore Blockade of the Human Cardiac Sodium Channel Nav1.5 by the Antiarrhythmic Drug Quinidine. Angew Chem Int Ed Engl. 2021 Mar 8. doi: 10.1002/anie.202102196. PMID:33684260 doi:http://dx.doi.org/10.1002/anie.202102196

6lqa, resolution 3.30Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA